2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2082

ERAP1 Deficiency Partially Relieves HLA-B27-Induced ER Stress and IL-23 Expression, but Does Not Restore Dendritic Cell Function in Experimental Spondyloarthritis
Abstract Number: 2316

Errors and Discrepancies in DXA Scans in Imaging Centers in Ecuador
Abstract Number: 1855

Erythrocyte Bound C4d in the Presence of Adverse Pregnancy Outcome Events in Pregnant Women with Systemic Lupus Erythematosus
Abstract Number: 2936

Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis
Abstract Number: 892

Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)
Abstract Number: 871

Estimates of Diet Quality Explain Less Variability in Serum Urate Levels Than Genetic Factors
Abstract Number: 1403

Estimates of Minimally Important Differences and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short-Forms Among Individuals with SLE
Abstract Number: 806

Estradiol Levels Are Elevated in Older Men with Diffuse Cutaneous SSc and Are Associated with Decreased Survival
Abstract Number: 102

Estrogen Controls the Expression of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in Human T Lymphocytes Via Transcriptional and Post-Transcriptional Mechanisms
Abstract Number: L11

Etanercept and Methotrexate As Monotherapy or in Combination in Patients with Psoriatic Arthritis: A Phase 3, Double-Blind, Randomized Controlled Study
Abstract Number: 272

Ethnic Disparities in Lupus Nephritis Outcomes in the Inland Empire: Findings from the Southern California Lupus Registry
Abstract Number: 1153

EULAR ‘Points to Consider’ for the Conduction of Workforce Requirement Studies in Rheumatology
Abstract Number: 2783

EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases
Abstract Number: 1278

Evaluating a Causal Role of Mitochondrial Variation in the Development of Gout
Abstract Number: 2389

Evaluating Disease Activity Outcomes for Juvenile Idiopathic Arthritis across the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].